Kyntra Bio, Inc. (KYNB): Cash & Equivalents
$47.87M
As of 2025-12-31
$50.64M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $47.87M | -5.2% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $50.48M | -38.1% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $81.55M | n/c | 2025-03-17, Balance as of period end |
| 2022-12-31 | $155.70M | -9.1% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $171.22M | -74.8% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $678.39M | +437.3% | 2022-03-04, Balance as of period end |
| 2019-12-31 | $126.27M | +41.5% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $89.26M | -86.8% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $673.66M | +287.6% | 2019-02-27, Balance as of period end |
| 2016-12-31 | $173.78M | +13.3% | 2018-02-27, Balance as of period end |
| 2015-12-31 | $153.32M | -7.3% | 2018-02-27, Balance as of period end |
| 2014-12-31 | $165.46M | +116.8% | 2017-03-01, Balance as of period end |
| 2013-12-31 | $76.33M | n/a | 2016-02-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | 2025-12-31 | $47.87M | -5.2% |
| Filana Therapeutics, Inc. (FLNA) | 2025-12-31 | $95.50M | -25.7% |
| Camp4 Therapeutics Corp (CAMP) | 2025-12-31 | $109.52M | +71.0% |
| Aardvark Therapeutics, Inc. (AARD) | 2025-12-31 | $47.05M | -23.7% |
| PMV Pharmaceuticals, Inc. (PMVP) | 2025-12-31 | $37.98M | -7.1% |
| Sagimet Biosciences Inc. (SGMT) | 2025-12-31 | $35.02M | -53.8% |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | $15.86M | -88.2% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $52.77M | n/m |
| Milestone Pharmaceuticals Inc. (MIST) | 2025-12-31 | $73.05M | +188.6% |
Compare KYNB, FLNA, CAMP, AARD side by side · Screen every company in Pharmaceutical Preparations ↗